GPhA Comments on JAMA Internal Medicine National Survey of Physicians

Published Online: Tuesday, January 8, 2013
Follow Pharmacy_Times:

Study Concludes Public Bares ‘Unnecessary Expense’ When Generics Are Not Used

WASHINGTON, D.C. (JANUARY 8, 2013) – The Generic Pharmaceutical Association (GPhA) today issued the following statement regarding a national survey of the prescribing behaviors of physicians and published January 7, 2013, in JAMA Internal Medicine (formerly Archives of Internal Medicine).

“The JAMA Internal Medicine study demonstrates that we are still leaving savings on the table that could be achieved by increasing the use of generic drugs. The use of safe and effective generic versions of brand name drugs currently saves consumers and the U.S. healthcare system $1 billion every other day, a total of $192 billion in 2011. But, as significant as these savings are, there still is room for improvement and we must realize that generics are part of the solution to sustaining affordable healthcare in America,” said GPhA President and CEO Ralph G. Neas.

The survey concluded that prescribing brand-name drugs when generic drugs are available “generates unnecessary medical expenditures, the costs of which are borne by the public in the form of higher copayments, increased health insurance costs, and higher Medicare and Medicaid expenses.” Prescribing a brand-name drug when a generic is available “is a huge source of wasteful spending that can be prevented,” says Eric Campbell, Ph.D., professor of medicine at Harvard Medical School and team leader of the study.

Results of the survey revealed that about four in 10 doctors “sometimes or often” prescribe a brand-name drug when a less costly generic version of the drug is available just because their patients requested the brand drug. The study also found that brand industry gifting (such as free food or beverage) and drugs samples “increase the likelihood that physicians will prescribe a brand name.”

“Nearly 80 percent of the 4 billion prescriptions written in the U.S. last year were filled using safe and effective generic versions of their brand name counterpart drugs,” Neas said. “This means that millions of consumers, including many seniors on fixed incomes, were able to purchase the medicines they need to live longer, healthier lives without having to give up other necessities,” he added.

“As the new Congress continues its work on the debt and deficit, we urge that Members reject any legislative proposal that could lessen the timely availability of affordable generics. This includes saying ‘no’ to any proposal that would restrict the right of drug manufacturers to settle patent litigation out of court, which has proven to be the one sure way of bringing generics to market prior to brand drug patent expiration,” Neas said. He added that initiatives to promote generic use in Medicare and Medicaid and to reduce the market exclusivity period for biologics from 12 years to seven, would generate significant additional savings for taxpayers and the government.

  • Read the JAMA Internal Medicine study here
  • Additional information on the savings generated by patent settlements here
  • 2012 Generic Savings Study here
Related Articles
The Generic Pharmaceutical Association welcomes the FDA’s proposed rule to amend its prescription drug and biological product labeling regulations to require electronic distribution of the prescribing information intended for healthcare professionals.
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
Today Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) introduced H.R. 5815, The Generic Drug Pricing Fairness Act, which creates greater transparency in how pharmacy benefit managers reimburse pharmacies for generic prescription drugs under Medicare Part D, and the Federal Employees Health Benefits Program. The National Community Pharmacists Association endorsed the bill, which goes further than legislation the same two Congressmen introduced earlier year that has the same remedies, but only applied to Medicare Part D.
Latest Issues